James P Evans

List of Publications by Year
in descending order

61 papers	4,790 citations	249298 26 h-index	150775 59 g-index
61 all docs	61 docs citations	61 times ranked	10053 citing authors

#	Article	IF	Citations
1	Burden or benefit? Effects of providing education about and the option to request additional genomic findings from diagnostic exome sequencing: A randomized controlled trial. Patient Education and Counseling, 2021, 104, 2989-2998.	1.0	0
2	Addressing perceived economic obstacles to genetic testing as a way to mitigate disparities in family health history for adoptees. Health Economics, Policy and Law, 2020, 15, 277-287.	1.1	4
3	DNA-Based Population Screening. JAMA - Journal of the American Medical Association, 2020, 323, 307.	3.8	31
4	Congenital Midline Cervical Cleft: First Report and Genetic Analysis of Two Related Patients. Annals of Otology, Rhinology and Laryngology, 2020, 129, 653-656.	0.6	5
5	Returning negative results to individuals in a genomic screening program: lessons learned. Genetics in Medicine, 2019, 21, 409-416.	1.1	33
6	Improving recommendations for genomic medicine: building an evolutionary process from clinical practice advisory documents to guidelines. Genetics in Medicine, 2019, 21, 2431-2438.	1.1	13
7	Factors influencing NCGENES research participants- requests for non-medically actionable secondary findings. Genetics in Medicine, 2019, 21, 1092-1099.	1.1	11
8	Diagnostic utility of exome sequencing in the evaluation of neuromuscular disorders. Neurology: Genetics, 2018, 4, e212.	0.9	42
9	Professional responsibilities regarding the provision, publication, and dissemination of patient phenotypes in the context of clinical genetic and genomic testing: points to considerâ€”a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2018, 20, 169-171.	1.1	13
10	Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntingtonâ€™s Disease. American Journal of Psychiatry, 2018, 175, 400-407.	4.0	9
11	â€œPossibly positive or certainly uncertain?â€ participantsâ€™ responses to uncertain diagnostic results from exome sequencing. Genetics in Medicine, 2018, 20, 313-319.	1.1	39
12	Increasing the diagnostic yield of exome sequencing by copy number variant analysis. PLoS ONE, 2018, 13, e0209185.	1.1	58
13	Evidenceâ€based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group. Human Mutation, 2018, 39, 1677-1685.	1.1	34
14	Finding the Rare Pathogenic Variants in a Human Genome. JAMA - Journal of the American Medical Association, 2017, 317, 1904.	3.8	38
15	Prenatal exome sequencing in anomalous fetuses: new opportunities and challenges. Genetics in Medicine, 2017, 19, 1207-1216.	1.1	135
16	A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories. Genetics in Medicine, 2017, 19, 575-582.	1.1	68
17	Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genetics in Medicine, 2017, 19, 249-255.	1.1	1,398
18	Mastering genomic terminology. Genetics in Medicine, 2017, 19, 491-492.	1.1	27

#	Article	IF	Citations
19	Examining the Cascade of Participant Attrition in a Genomic Medicine Research Study: Barriers and Facilitators to Achieving Diversity. Public Health Genomics, 2017, 20, 332-342.	0.6	8
20	Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 49-60.	0.4	9
21	A New Framework and Prototype Solution for Clinical Decision Support and Research in Genomics and Other Data-intensive Fields of Medicine. EGEMS (Washington, DC), 2017, 4, 6.	2.0	7
22	Genetic Complexity of Mitral Valve Prolapse Revealed by Clinical and Genetic Evaluation of a Large Family. Journal of Heart Valve Disease, 2017, 26, 569-580.	0.5	1
23	Does Lack of â€œGenetic-Relative Family Health Historyâ€•Represent a Potentially Avoidable Health Disparity for Adoptees?. American Journal of Bioethics, 2016, 16, 33-38.	0.5	27
24	Germline Analysis from Tumorâ€“Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. Clinical Cancer Research, 2016, 22, 4087-4094.	3.2	75
25	A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. Genetics in Medicine, 2016, 18, 1258-1268.	1.1	89
26	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	2.6	137
27	Plagiarism in submitted manuscripts: incidence, characteristics and optimization of screeningâ€”case study in a major specialty medical journal. Research Integrity and Peer Review, 2016, 1, 13.	2.2	45
28	Issues of â€œCost, Capabilities, and Scopeâ€•in Characterizing Adoptees' Lack of â€œGenetic-Relative Family Health Historyâ€•as an Avoidable Health Disparity: Response to Open Peer Commentaries on â€œDoes Lack of â€˜Genetic-Relative Family Health Historyâ€™ Represent a Potentially Avoidable Health Disparity for Adoptees?â€• American Journal of Bioethics, 2016, 16, W4-W8.	0.5	7
29	The promise and peril of genomic screening in the general population. Genetics in Medicine, 2016, 18, 593-599.	1.1	53
30	A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. Genetics in Medicine, 2016, 18, 467-475.	1.1	74
31	Genomic screening of the general adult population: key concepts for assessing net benefit with systematic evidence reviews. Genetics in Medicine, 2015, 17, 441-443.	1.1	19
32	ClinGen â€” The Clinical Genome Resource. New England Journal of Medicine, 2015, 372, 2235-2242.	13.9	1,016
33	A Public Health Perspective on a National Precision Medicine Cohort. JAMA - Journal of the American Medical Association, 2015, 313, 2117.	3.8	82
34	Genetic Testing and FDA Regulation. JAMA - Journal of the American Medical Association, 2015, 313, 669.	3.8	37
35	High Diagnostic Yield of Whole Exome Sequencing in Participants With Retinal Dystrophies in a Clinical Ophthalmology Setting. American Journal of Ophthalmology, 2015, 160, 354-363.e9.	1.7	27
36	Can targeted genetic testing offer useful health information to adoptees?. Genetics in Medicine, 2015, 17, 533-535.	1.1	21

#	Article	IF	Citations
37	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Research, 2015, 25, 305-315.	2.4	313
38	Returning pharmacogenetic secondary findings from genome sequencing: letâ€™s not put the cart before the horse. Genetics in Medicine, 2015, 17, 854-856.	1.1	5
39	Utility before business. Genetics in Medicine, 2014, 16, 869-870.	1.1	3
40	Biobanks containing clinical specimens: Defining characteristics, policies, and practices. Clinical Biochemistry, 2014, 47, 245-251.	0.8	28
41	Characterizing biobank organizations in the U.S.: results from a national survey. Genome Medicine, 2013, 5, 3.	3.6	157
42	The arrival of genomic medicine to the clinic is only the beginning of the journey. Genetics in Medicine, 2013, 15, 268-269.	1.1	24
43	Finding common ground. Genetics in Medicine, 2013, 15, 852-853.	1.1	7
44	We screen newborns, donâ€™t we?: realizing the promise of public health genomics. Genetics in Medicine, 2013, 15, 332-334.	1.1	64
45	When is a medical finding â€œincidentalâ€?. Genetics in Medicine, 2013, 15, 515-516.	1.1	5
46	Return of results: not that complicated?. Genetics in Medicine, 2012, 14, 358-360.	1.1	55
47	Deflating the Genomic Bubble. Science, 2011, 331, 861-862.	6.0	161
48	Looking ahead, looking behind. Genetics in Medicine, 2011, 13, 177-178.	1.1	6
49	Next-Generation DNA Sequencing, Regulation, and the Limits of Paternalism. JAMA - Journal of the American Medical Association, 2011, 306, 2376-7.	3.8	29
50	The Human Genome Project at 10 years: A teachable moment. Genetics in Medicine, 2010, 12, 477.	1.1	6
51	Putting patients before patents. Genetics in Medicine, 2010, 12, S3-S4.	1.1	3
52	The rules remain the same for genomic medicine: The case against â€œreverse genetic exceptionalismâ€. Genetics in Medicine, 2010, 12, 342-343.	1.1	27
53	Putting patients before patents. Genetics in Medicine, 2010, 12, 204-205.	1.1	1
54	The Voyage Continues. JAMA - Journal of the American Medical Association, 2009, 301, 663.	3.8	4

#	Article	IF	Citations
55	The Origin. Genetics in Medicine, 2009, 11, 776-777.	1.1	0
56	Direct to consumer genetic testing: Avoiding a culture war. Genetics in Medicine, 2009, 11, 568-569.	1.1	63
57	Health care in the age of genetic medicine. Genetics in Medicine, 2008, 10, 1-3.	1.1	7
58	Recreational genomics; what's in it for you?. Genetics in Medicine, 2008, 10, 709-710.	1.1	20
59	Genetic exceptionalism. Too much of a good thing?. Genetics in Medicine, 2008, 10, 500-501.	1.1	56
60	Health Care in the Age of Genetic Medicine. JAMA - Journal of the American Medical Association, 2007, 298, 2670.	3.8	28
61	Genetics and the Young Woman with Breast Cancer. Breast Disease, 2006, 23, 17-29.	0.4	26